Natera, Inc. (NASDAQ:NTRA) Receives $267.83 Consensus Price Target from Analysts

Shares of Natera, Inc. (NASDAQ:NTRA) have earned an average rating of “Moderate Buy” from the twenty-two ratings firms that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation, fourteen have issued a buy recommendation and three have given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $267.8333.

A number of research firms have weighed in on NTRA. Evercore reaffirmed an “outperform” rating and issued a $300.00 price objective on shares of Natera in a report on Monday, July 6th. Barclays dropped their target price on Natera from $280.00 to $260.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 24th. Canaccord Genuity Group lifted their price target on Natera from $285.00 to $330.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. TD Cowen reaffirmed a “buy” rating on shares of Natera in a report on Wednesday, July 15th. Finally, Piper Sandler reiterated an “overweight” rating and set a $249.00 price target on shares of Natera in a research report on Tuesday, May 12th.

Insider Buying and Selling at Natera

In other news, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $272.90, for a total transaction of $818,700.00. Following the transaction, the insider owned 134,643 shares in the company, valued at $36,744,074.70. This trade represents a 2.18% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gail Boxer Marcus sold 11,000 shares of Natera stock in a transaction on Friday, June 5th. The shares were sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the completion of the sale, the director directly owned 6,183 shares in the company, valued at $1,343,009.43. This represents a 64.02% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 173,951 shares of company stock worth $39,412,294. 5.05% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Horizon Investments LLC boosted its stake in Natera by 22.0% during the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after purchasing an additional 44 shares during the last quarter. Sound Income Strategies LLC raised its position in shares of Natera by 20.0% in the fourth quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after buying an additional 45 shares during the last quarter. Savvy Advisors Inc. lifted its stake in shares of Natera by 3.1% in the fourth quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock worth $353,000 after buying an additional 46 shares in the last quarter. Parallel Advisors LLC lifted its stake in shares of Natera by 5.5% in the first quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock worth $181,000 after buying an additional 47 shares in the last quarter. Finally, First Horizon Corp boosted its position in Natera by 5.5% during the first quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock worth $196,000 after acquiring an additional 51 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Price Performance

NTRA opened at $267.76 on Monday. The firm has a fifty day moving average price of $246.77 and a 200 day moving average price of $222.22. Natera has a 1 year low of $131.81 and a 1 year high of $288.04. The stock has a market cap of $38.35 billion, a P/E ratio of -164.27 and a beta of 1.51.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.